Boston Scientific Corporation
) recently reported favorable results from studies pertaining to
cardiac resynchronization therapy (CRT), platinum chromium stent
platforms and transcatheter aortic valve replacement (TAVR) at
the American College of Cardiology's (ACC) 63rd Annual Scientific
Session. The company also presented new data on nearly a dozen
cardiology-related clinical trials at the session, which was held
from March 29-31 at Washington, D.C.
Boston Scientific's shares gained 0.8% in the trading session
that followed the release of the study results. The stock is up
around 14.6% year to date.
In the aforementioned session, Boston Scientific announced
significant findings from the continued analysis of the landmark
MADIT-CRT study that showed a significant and sustained survival
benefit in mild heart failure patients. The study established
that patients who were assigned a Boston Scientific defibrillator
with CRT had relatively 41% less risk of death than those who
received a defibrillator alone.
The results also demonstrated that patients receiving CRT therapy
had 62% lesser chances of suffering a first heart failure event
than those without the CRT therapy.
The MADIT-CRT trial compares Implantable
cardioverter-defibrillator (ICD) to CRT defibrillators (CRT-D)
therapy in patients with mild heart failure. In this global
multicenter study comprising 1,691 patients, over 80% of the
patients who received CRT therapy were still alive at 7 years.
Boston Scientific has developed CRT-D that have the greatest
projected battery longevity in the industry of up to 8 years.
These long-lasting devices will likely reduce the need for
additional device implants in heart failure patients.
As part of another trial, Boston Scientific released new data
that continue to validate the advantages of its platinum chromium
stents, in turn, demonstrating its design leadership in drug
eluting stent (DES) technology. In this regard, the PLATINUM
Workhorse clinical trial compared the safety and effectiveness of
the company's Platinum Chromium Everolimus-Eluting Stent System
(PtCr EES) to the Abbott Laboratories Cobalt Chromium
Everolimus-Eluting Stent System (CoCr EES).
The trial results showed that PtCr EES has had low event rates
through 4 years. An earlier reported significant reduction in
unplanned stenting with PtCr EES compared to the CoCr EES,
including a significantly lower rate of inadequate lesion
coverage, was also confirmed.
These clinical observations reinforce greater visibility and
derivability of PtCr EES vis-à-vis CoCr EES, apart from the
cost-savings achieved per procedure.
Boston Scientific's Promus PREMIER Everolimus-Eluting Platinum
Chromium Coronary Stent System was recently approved by the U.S.
Food and Drug Administration (FDA). This enhanced stent delivery
system proves useful for physicians in treating coronary artery
disease in patients.
In another development at the ACC 2014, new data presented showed
that Boston Scientific's Lotus Valve System advanced TAVR
technology continues to demonstrate solid performance at three
months. The REPRISE II clinical trial, which is an ongoing
perspective, has been evaluating the Lotus Valve System in
symptomatic patients with severe aortic valve stenosis having
high risk for surgical valve replacement.
REPRISE II has enrolled 120 patients at 14 sites across
Australia, France, Germany and the U.K. An additional 130
patients will be enrolled in an extension of REPRISE II at 16
sites in Australia and Europe by the end of this month.
This trial results were impressive, with a whopping 85% of
patients having no paravalvular aortic regurgitation by
independent core lab assessment at 90 days. Moreover, there were
no cases of patients having severe paravalvular aortic
regurgitation at 90 days.
Boston Scientific currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks worth considering in the medical
products industry include
Meridian Bioscience, Inc.
). While Enzymotec carries a Zacks Rank #1 (Strong Buy),
SurModics and Meridian hold a Zacks Rank #2 (Buy).
BOSTON SCIENTIF (BSX): Free Stock Analysis
ENZYMOTEC LTD (ENZY): Free Stock Analysis
SURMODICS (SRDX): Free Stock Analysis Report
MERIDIAN BIOSCI (VIVO): Free Stock Analysis
To read this article on Zacks.com click here.